{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T03:51:39Z","timestamp":1784605899610,"version":"3.55.0"},"reference-count":52,"publisher":"Georg Thieme Verlag KG","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2012]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>A number of novel oral anticoagulants that directly target factor Xa or thrombin have been developed in recent years. Rivaroxaban and apixaban (direct factor Xa inhibitors) and dabigatran etexilate (a direct thrombin inhibitor) have shown considerable promise in large-scale, randomised clinical studies for the management of thromboembolic disorders, and have been approved for clinical use in specific indications. Rivaroxaban is licensed for the prevention of venous thromboembolism in patients undergoing elective hip or knee replacement surgery, the treatment of deep-vein thrombosis and prevention of recurrent venous thromboembolism, and for stroke prevention in patients with non-valvular atrial fibrillation. Based on the clinical trial data for rivaroxaban, feedback on its use in clinical practice and the authors\u2019 experience with the use of rivaroxaban, practical guidance for the use of rivaroxaban in special patient populations and specific clinical situations is provided. Although most recommendations are in line with the European summary of product characteristics for the approved indications, additional and, in several areas, different recommendations are given based on review of the literature and the authors\u2019 clinical experience.<\/jats:p>","DOI":"10.1160\/th12-03-0209","type":"journal-article","created":{"date-parts":[[2012,9,28]],"date-time":"2012-09-28T04:52:02Z","timestamp":1348807922000},"page":"876-886","source":"Crossref","is-referenced-by-count":129,"title":["Management consensus guidance for the use of rivaroxaban \u2013 an oral, direct factor Xa inhibitor"],"prefix":"10.1160","volume":"108","author":[{"given":"Reinhold","family":"Kreutz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Llau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Norrving","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Haas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Turpie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2017,11,29]]},"reference":[{"key":"10.1160\/TH12-03-0209-1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2404"},{"key":"10.1160\/TH12-03-0209-2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr236"},{"key":"10.1160\/TH12-03-0209-3","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2302"},{"key":"10.1160\/TH12-03-0209-4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0800374"},{"key":"10.1160\/TH12-03-0209-5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60880-6"},{"key":"10.1160\/TH12-03-0209-6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa076016"},{"key":"10.1160\/TH12-03-0209-7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60734-0"},{"key":"10.1160\/TH12-03-0209-8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007903"},{"key":"10.1160\/TH12-03-0209-9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113572"},{"key":"10.1160\/TH12-03-0209-10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"10.1160\/TH12-03-0209-11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112277"},{"key":"10.1160\/TH12-03-0209-12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2044.2007.05195.x"},{"key":"10.1160\/TH12-03-0209-13","unstructured":"Bayer Pharma AG. Xarelto\u00ae (rivaroxaban) Summary of Product Characteristics. 2012. Available at: http:\/\/www.xarelto.com\/html\/downloads\/Xarelto-Prescribing_Information-May-2012.pdf. Accessed July 31, 2012."},{"key":"10.1160\/TH12-03-0209-14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.06.011"},{"key":"10.1160\/TH12-03-0209-15","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802361499"},{"key":"10.1160\/TH12-03-0209-16","doi-asserted-by":"publisher","DOI":"10.1097\/EJA.0b013e32833f6f6f"},{"key":"10.1160\/TH12-03-0209-17","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2292"},{"key":"10.1160\/TH12-03-0209-18","doi-asserted-by":"crossref","unstructured":"Kubitza D, Becka M, Voith B, et al. Effect of enoxaparin on the safety, tolerability, pharmacodynamics and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005; 3 (Suppl 1): Abstract P1704","DOI":"10.1007\/s00228-005-0043-5"},{"key":"10.1160\/TH12-03-0209-19","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2291"},{"key":"10.1160\/TH12-03-0209-20","doi-asserted-by":"publisher","DOI":"10.1007\/BF00499225"},{"key":"10.1160\/TH12-03-0209-21","doi-asserted-by":"publisher","DOI":"10.1160\/TH11-10-0718"},{"key":"10.1160\/TH12-03-0209-22","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1024\/0301-1526\/a000184","volume":"41","author":"Haas","year":"2012","journal-title":"Vasa"},{"key":"10.1160\/TH12-03-0209-23","doi-asserted-by":"crossref","unstructured":"Kubitza D, Becka M, Zuehlsdorf M, et al. No interaction between the novel, oral direct Factor Xa inhibitor BAY 59-7939 and digoxin. J Clin Pharmacol 2006; 46: 702: Abstract 11","DOI":"10.1177\/0091270006286904"},{"key":"10.1160\/TH12-03-0209-24","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006292127"},{"key":"10.1160\/TH12-03-0209-25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02776.x"},{"key":"10.1160\/TH12-03-0209-26","unstructured":"Kubitza D, Mueck W, Becka M. No interaction between rivaroxaban - a novel, oral, direct Factor Xa inhibitor - and atorvastatin. Pathophysiol Haemost Thromb 2008; 36: A40: Abstract P062"},{"key":"10.1160\/TH12-03-0209-27","doi-asserted-by":"publisher","DOI":"10.3390\/ph5030279"},{"key":"10.1160\/TH12-03-0209-28","first-page":"1046","volume":"91","author":"L\u00f3pez-Jim\u00e9nez","year":"2006","journal-title":"Haematologica"},{"key":"10.1160\/TH12-03-0209-29","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1160\/TH08-04-0255","volume":"100","author":"Spencer","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1160\/TH12-03-0209-30","first-page":"419","volume":"120","author":"Glassock","year":"2009","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"10.1160\/TH12-03-0209-31","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-09-0601"},{"key":"10.1160\/TH12-03-0209-32","doi-asserted-by":"crossref","unstructured":"Kubitza D, Becka M, Roth A, et al. The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct Factor Xa inhibitor. J Clin Pharmacol 2012; in press","DOI":"10.1002\/jcph.5"},{"key":"10.1160\/TH12-03-0209-33","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.025569"},{"key":"10.1160\/TH12-03-0209-34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03753.x"},{"key":"10.1160\/TH12-03-0209-35","unstructured":"Halabi A, Kubitza D, Zuehlsdorf M, et al. Effect of hepatic impairment on the pharmacokinetics, pharmacodynamics and tolerability of rivaroxaban - an oral, direct Factor Xa inhibitor. J Thromb Haemost 2007; 5 (Suppl 2): Abstract P-M-635"},{"key":"10.1160\/TH12-03-0209-36","doi-asserted-by":"crossref","first-page":"492","DOI":"10.5694\/j.1326-5377.2004.tb06407.x","volume":"181","author":"Baker","year":"2004","journal-title":"Med J Aust"},{"key":"10.1160\/TH12-03-0209-37","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2003.008904"},{"key":"10.1160\/TH12-03-0209-38","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2291"},{"key":"10.1160\/TH12-03-0209-39","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.029017"},{"key":"10.1160\/TH12-03-0209-40","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-03-0179"},{"key":"10.1160\/TH12-03-0209-41","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-005-0043-5"},{"key":"10.1160\/TH12-03-0209-42","doi-asserted-by":"crossref","first-page":"335","DOI":"10.5414\/CPP45335","volume":"45","author":"Mueck","year":"2007","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1160\/TH12-03-0209-43","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200847030-00006"},{"key":"10.1160\/TH12-03-0209-44","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2011.09.004"},{"key":"10.1160\/TH12-03-0209-45","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-10-0667"},{"key":"10.1160\/TH12-03-0209-46","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2011.06.031"},{"key":"10.1160\/TH12-03-0209-47","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2011.01.001"},{"key":"10.1160\/TH12-03-0209-48","doi-asserted-by":"publisher","DOI":"10.1160\/TH11-04-0277"},{"key":"10.1160\/TH12-03-0209-49","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-08-0511"},{"key":"10.1160\/TH12-03-0209-50","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181f2f264"},{"key":"10.1160\/TH12-03-0209-51","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-03-0176"},{"key":"10.1160\/TH12-03-0209-52","doi-asserted-by":"crossref","unstructured":"Samama MM, Contant G, Spiro TE, et al. Evaluation of the anti-Factor Xa chromogenic assay for measuring rivaroxaban plasma concentrations using calibrators and controls. Blood (ASH Annual Meeting Abstracts) 2010; 116: 1363-1364 (Abstract 3330)","DOI":"10.1182\/blood.V116.21.3330.3330"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1160\/TH12-03-0209.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T07:42:50Z","timestamp":1594712570000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1160\/TH12-03-0209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":52,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,11,29]]},"published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1160\/th12-03-0209","relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}